Magazine Article | July 1, 2022

Transitioning To Orphan Drug Commercialization: A Q&A With Albireo Pharma's CEO Ron Cooper

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

Beginning in 2008 as a Gothenburg, Sweden-based spin-out of AstraZeneca, Albireo Pharma was created on the founders’ — Jan Mattsson and Per-Göran Gillberg — expertise in novel bile acid modulators. In 2015, Albireo established an office in Boston and hired Ron Cooper as president and CEO. One year later, Albireo became a publicly traded company through a share exchange and merger with Biodel Inc., a Danbury, CT-based specialty pharmaceutical company.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: